ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -

ELIZA triplet kwic verb link Multi InLine WordNet Search InLine Multi WordNet reset

Clear cache

unConcat

Concat

restore:

provide increased identified significant effects potential risk performed studies show analysis due increase total growth there through response levels different new functional specific use activity changes effect molecular findings health expression due+to

kwic ON

abstract OFF

strict srch

Eliza Top

triplet

verb

InLine link

link

left(kwic)

right(kwic)

<<

<

>

>>

Srch Selected

return kwic search for those out of >500 occurrences
303636 occurrences (No.74 in the rank) during 5 years in the PubMed. [no cache] 500 found

256) The 6-MP dose administered to patients with ALL with a NUDT15 variant was higher than that given to those without SMNs (P = .045).

--- ABSTRACT ---

PMID:34662904 DOI:10.1182/bloodadvances.2021005507

2021 Blood advances

* NUDT15 variants confer high incidence of second malignancies in children with acute lymphoblastic leukemia.

- The effect of genetic variation on second malignant neoplasms (SMNs) remains unclear. First, we identified the pathogenic germline variants in cancer-predisposing genes among 15 children with SMNs after childhood leukemia/lymphoma using whole-exome sequencing. Because the prevalence was low, we focused on the association between SMNs and NUDT15 in primary acute lymphoblastic leukemia (ALL) cases. NUDT15 is one of the 6-mercaptopurine (6-MP) metabolic genes, and its variants are common in East Asian individuals. The prevalence of NUDT15 hypomorphic variants was higher in patients with SMNs (n = 14; 42.9%) than in the general population in the gnomAD database (19.7%; P = .042). In the validation study with a cohort of 438 unselected patients with ALL, the cumulative incidence of SMNs was significantly higher among those with (3.0%; 95% confidence interval [CI], 0.6% to 9.4%) than among those without NUDT15 variants (0.3%; 95% CI, 0.0% to 1.5%; P = .045). The 6-MP dose administered to patients with ALL with a NUDT15 variant was higher than that given to those without SMNs (P = .045). The 6-MP-related mutational signature was observed in SMN specimens after 6-MP exposure. In cells exposed to 6-MP, a higher level of 6-MP induced DNA damage in NUDT15-knockdown induced pluripotent stem cells. Our study indicates that NUDT15 variants may confer a risk of SMNs after treatment with 6-MP in patients with ALL.

--- ABSTRACT END ---

abstract OFF

[

right

kwic]